Drug name - Rytary

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8377474 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof Dec, 2028

(6 years from now)

US8454998 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof Dec, 2028

(6 years from now)

US8557283 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof Dec, 2028

(6 years from now)

US9901640 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof Dec, 2028

(6 years from now)

US9533046 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof Dec, 2028

(6 years from now)

US9463246 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof Dec, 2028

(6 years from now)

US9089607 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof Dec, 2028

(6 years from now)

US9089608 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof Dec, 2028

(6 years from now)

Drugs and Companies using CARBIDOPA; LEVODOPA ingredient

Treatment: Treatment of parkinson's disease; treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; Treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; treatment of post-encephalitic parkinsonism; treatment of post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; treatment of parkinson's disease; treatment of parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; Treatment of parkinson's disease; Treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; method of providing a therapeutically effective and stable median blood plasma level of levodopa

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
23.75MG;95MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
36.25MG;145MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
48.75MG;195MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
61.25MG;245MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.